皮下注射英夫利昔单抗能否替代剂量强化的静脉给药用于治疗炎症性肠病？ - Suppr | 超能文献

Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?

作者信息

Little Robert D, Ward Mark G, Sparrow Miles P

机构信息

Department of Gastroenterology, The Alfred Hospital and Monash University, Melbourne, Victoria, Australia.

出版信息

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2430-2431. doi: 10.1016/j.cgh.2022.09.015. Epub 2022 Sep 22.

DOI:10.1016/j.cgh.2022.09.015

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?皮下注射英夫利昔单抗能否替代剂量强化的静脉给药用于治疗炎症性肠病？

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2430-2431. doi: 10.1016/j.cgh.2022.09.015. Epub 2022 Sep 22.

2

From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.炎症性肠病患者从静脉注射英夫利昔单抗改为皮下注射：一项受疫情驱动的举措。

Lancet Gastroenterol Hepatol. 2021 Feb;6(2):88-89. doi: 10.1016/S2468-1253(20)30392-7.

3

[Biological drugs in inflammatory bowel disease: Management and care].[炎症性肠病中的生物药物：管理与护理]

Rev Esp Enferm Dig. 2015 Jul;107(7):454.

4

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial.从强化静脉注射英夫利昔单抗转换为皮下注射英夫利昔单抗治疗炎症性肠病（DISCUS-IBD）：一项多中心随机对照试验方案。

BMJ Open. 2024 Jul 20;14(7):e081787. doi: 10.1136/bmjopen-2023-081787.

5

Safety, satisfaction and cost savings of accelerated infusions of standard and intensified-dose infliximab for inflammatory bowel disease.标准剂量和强化剂量英夫利昔单抗加速输注治疗炎症性肠病的安全性、满意度和成本节约。

Intern Med J. 2022 Dec;52(12):2143-2149. doi: 10.1111/imj.15493. Epub 2022 Jun 30.

6

Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).炎症性肠病（IBD）中生物类似药的临床与科学相关问题：比利时IBD研发小组（BIRD）立场文件

Acta Gastroenterol Belg. 2015 Jan-Mar;78(1):26-9.

7

Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease.英夫利昔单抗在儿童炎症性肠病中的替代使用策略。

Curr Gastroenterol Rep. 2008 Jun;10(3):302-7. doi: 10.1007/s11894-008-0060-5.

8

Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease.英夫利昔单抗治疗小儿炎症性肠病的给药方法存在差异。

J Pediatr Gastroenterol Nutr. 2013 Jul;57(1):35-8. doi: 10.1097/MPG.0b013e31828f1ea2.

9

[Anti-TNF agents in inflammatory bowel disease: indications and management].[抗肿瘤坏死因子制剂在炎症性肠病中的应用：适应证与管理]

Gastroenterol Clin Biol. 2004 May;28(5 Suppl):D61-9. doi: 10.1016/s0399-8320(04)94989-5.

10

Infliximab therapy in children and adolescents with inflammatory bowel disease.英夫利昔单抗治疗儿童和青少年炎症性肠病

Drugs. 2007;67(12):1703-23. doi: 10.2165/00003495-200767120-00005.

引用本文的文献

1

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial.从强化静脉注射英夫利昔单抗转换为皮下注射英夫利昔单抗治疗炎症性肠病（DISCUS-IBD）：一项多中心随机对照试验方案。

BMJ Open. 2024 Jul 20;14(7):e081787. doi: 10.1136/bmjopen-2023-081787.

2

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics.炎症性肠病中皮下注射英夫利昔单抗的治疗药物监测——在皮下生物制剂新时代理解药代动力学和暴露-反应关系

J Clin Med. 2022 Oct 19;11(20):6173. doi: 10.3390/jcm11206173.